Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

291
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
291
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

257
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
257
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

256
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
256
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

257
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
257

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Steatotic liver disease in Latin America: current views and perspectives.

Nature reviews. Gastroenterology & hepatology·2026
Same author

Quantitative ultrasound for hepatic fat assessment: physical principles, signal processing, and technological advances - a scoping review.

Biomedical physics & engineering express·2026
Same author

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same author

Binge drinking, metabolic dysfunction, and the spectrum of steatotic liver disease in the USA: a cross-sectional and longitudinal analysis.

The lancet. Gastroenterology & hepatology·2026
Same author

Agile 3+ and Agile 4 scores are accurate to detect advanced metabolic dysfunction-associated steatotic liver disease.

European journal of gastroenterology & hepatology·2026
Same author

Name MASLD/MASH - and act on it.

JHEP reports : innovation in hepatology·2026

関連する実験動画

Updated: Sep 10, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.7K

MASLD患者におけるピオグリタゾンの長期使用: 多中心的予備研究からの洞察

Isabel Veloso Alves Pereira1, Ana Beatriz Souza de Oliveira1, Patricia Momoyo Yoshimura Zitelli1

  • 1Divisão de Gastroenterologia e Hepatologia, Hospital das Clínicas HCFMUSP (LIM-07), Departamento de Gastroenterologia e Nutrologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

Clinics (Sao Paulo, Brazil)
|August 22, 2025
PubMed
まとめ
この要約は機械生成です。

ピオグリタゾンの長期療法は,代謝機能障害関連ステアトス性肝疾患 (MASLD) の患者で肝臓酵素とステアトーシスを有意に改善しました. これはピオグリタゾンが有効な治療法であることを示唆しています 特に代替薬が限られている場合です

キーワード:
マッシュMASLD についてピオグリタゾン

さらに関連する動画

Isolation and Culture of Human Mature Adipocytes Using Membrane Mature Adipocyte Aggregate Cultures MAAC
06:28

Isolation and Culture of Human Mature Adipocytes Using Membrane Mature Adipocyte Aggregate Cultures MAAC

Published on: February 13, 2020

19.4K
Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING
07:36

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING

Published on: March 14, 2019

7.1K

関連する実験動画

Last Updated: Sep 10, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.7K
Isolation and Culture of Human Mature Adipocytes Using Membrane Mature Adipocyte Aggregate Cultures MAAC
06:28

Isolation and Culture of Human Mature Adipocytes Using Membrane Mature Adipocyte Aggregate Cultures MAAC

Published on: February 13, 2020

19.4K
Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING
07:36

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING

Published on: March 14, 2019

7.1K

科学分野:

  • ヘパトロジー
  • 代謝障害
  • 薬理学について

背景:

  • 代謝機能障害に関連するステアトス性肝疾患 (MASLD) は,健康上の懸念が高まっています.
  • 非侵襲的なバイオマーカーは,MASLDにおける肝臓の健康を評価するのに不可欠です.
  • MASLDに対するピオグリタゾンの長期的な治療効果については,さらなる調査が必要である.

研究 の 目的:

  • MASLD患者の肝硬化,ステアトーシス,その他の非侵襲的バイオマーカーに対するピオグリタゾンの長期的な影響を評価する.
  • 異なる治療期間 (1~3年対4~10年) におけるピオグリタゾンの有効性を評価する.

主な方法:

  • ピオグリタゾン (30~45mg/日) で治療された65人のMASLD患者による多センター遡及研究.
  • 振動制御トランジント弾性図 (VCTE),制御減衰パラメータ (CAP),および治療前のおよび後のFibroScan-ASTスコアの評価.
  • 治療期間によって2つのグループに分けられる.

主要な成果:

  • アラニンアミノトランスフェラーゼ (ALT) とガンマグルタミルトランスフェラーゼ (GGT) の有意な減少が両群で観察された.
  • 4~10歳のグループでは,肝臓ステアトーシスの減少を示唆するCAPの有意な減少が認められた.
  • FASTTMスコアの改善は,両方の治療期間グループで有意であった.

結論:

  • 長期にわたるピオグリタゾン治療は,MASLD患者の代謝と肝臓に重大な効果を示しています.
  • ピオグリタゾンは,MASLDの費用対効果の高い,アクセス可能な治療法として潜在性を示しています.
  • 発見は,特に資源の限られた環境でのMASLD管理におけるピオグリタゾンの役割を支持しています.